Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anaprazole in reflux esophagitis
NCT07010107Phase 3Recruiting
- Sponsor
- Xuanzhu Biopharmaceutical
- Start
- Jul 2025
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Anaprazole in reflux esophagitis, sponsored by Xuanzhu Biopharmaceutical. Started Jul 2025; status: recruiting.
02
Drugs
Anaprazole
03
Conditions
reflux esophagitis
Beyond the preview
Go deeper on NCT07010107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07010107.